COPD Management: The Evidence Behind the Tool

A 61-year-old farmer comes to the medical outpatient clinic for a refill. He has smoked bidis since he was a boy, ten or twelve a day now. For three years he has used a budesonide-formoterol inhaler that a clinic in town gave him “for asthma”. Last winter he had one bad week of breathlessness and green sputum, and took a course of tablets from the local doctor. His wife has come with him. She has never smoked, but she is breathless on the stairs too, and she has cooked on a wood fire all her married life. This is an illustrative case, not real patients.

The COPD Management tool will help you with both of them: the spirometric grade, the ABE group, the inhaler to start or change to, the grading and treatment of an exacerbation, and the discharge bundle. What it no longer carries is some of the why. The national burden figures, the study behind the smoking curve, the trials that retired one inhaler pair and the history of how exacerbations were graded sat in its Evidence tab and have moved here, so that the tool stays quick at the bedside. By the end of this article you will know why the tool asks what it asks.

1. A disease India carries in large numbers

India carried an estimated 55 million COPD cases in 2016 and about a third of the world’s chronic respiratory disease burden, and the loss per case runs well above the global average (India State-Level Disease Burden Initiative, 2018). The same analysis found that air pollution accounted for about half of India’s COPD burden, ahead of tobacco at about a quarter.

“But she has never smoked. Can she have COPD?” Yes, and she is exactly the patient that a history of cigarettes alone will miss. Ask about the kitchen, the fuel, and the years beside the fire. Then do what the tool insists on for her husband and for her: spirometry after a bronchodilator. The diagnosis is a ratio, not a story.

2. The curve that every respiratory physician carries

The 1977 Fletcher and Peto study drew the curve every respiratory physician still carries: FEV₁ falls slowly with age in everyone, steeply in the susceptible smoker, and the smoker who quits does not regain lung function but reverts to the normal rate of loss (Fletcher 1977). FEV₁ is the volume breathed out in the first second of a forced breath, the number your spirometry report grades.

Read the curve carefully, because it says two things. Stopping smoking does not give back the lung already lost. And stopping smoking is the one thing that changes the slope from that day on. Every drug in the tool treats symptoms and exacerbations; none of them bends the curve. That is why cessation leads every treatment recommendation the tool prints, at every grade and every visit.

“He’s 61 and has smoked for fifty years. Is it worth stopping now?” It is the most useful thing he can do this year. From the day he stops, his lungs decline at the ordinary rate for his age rather than the smoker’s rate.

3. Why the LABA and ICS pair was dropped

Our farmer’s inhaler holds two drugs: a long-acting beta-2 agonist, LABA, and an inhaled corticosteroid, ICS. The pairing of a LABA with an ICS was asthma’s regimen imported into COPD. IMPACT and ETHOS showed that triple therapy beat both dual regimens on exacerbations in exacerbation-prone patients, with a mortality signal in both trials, and the halfway house lost its constituency: a patient ill enough to need an ICS is better served adding it to dual bronchodilation (Lipson 2018; Rabe 2020). Dual bronchodilation means a LABA with a long-acting muscarinic antagonist, LAMA.

“So should I just stop his inhaler?” Not stop: move. The tool never starts LABA + ICS. For the patient who arrives on it, the move is sideways to LABA + LAMA, or up to triple therapy, on his exacerbation history and his blood eosinophil count. Our farmer had one exacerbation last winter, so under the 2026 report he is in group E. If his eosinophils are 300 cells/µL or above, he goes up to triple therapy; if not, sideways to LABA + LAMA.

4. Grading the exacerbation on the patient, not the treatment

For fifty years exacerbation severity was defined by the treatment it received, which is circular: an exacerbation was severe because somebody admitted it. A patient in a district with no beds had a mild exacerbation; the same patient in a city hospital had a severe one. The Rome proposal broke that circle (Celli 2021). It grades the event itself, from the dyspnoea score, the respiratory rate, the heart rate, the saturation, the C-reactive protein and the blood gas, and the 2026 report builds its exacerbation chapter on that grading.

The common mistake is to copy the respiratory rate from the triage sheet. Count it yourself for a full minute. It is the criterion most often wrong in the notes, and with the pulse it separates the patient who can go home from the one who cannot.

Back to the clinic

Our farmer has spirometry after salbutamol. His ratio is below 0.7: he has COPD, not asthma. His budesonide-formoterol is changed on his eosinophil count, he is offered help to stop the bidis, and he is vaccinated and sent for pulmonary rehabilitation. His wife has spirometry too, and the kitchen gets a conversation about a gas stove. Each of those steps is a line in the tool.

Try this

A 68-year-old man with known COPD comes to casualty with three days of worse breathlessness. His saturation is 86 per cent on room air. The nurse puts him on 10 litres a minute by face mask and his saturation rises to 99 per cent. An hour later he is drowsy. What has happened, and what do you do? Illustrative case.

Answer. He has probably retained carbon dioxide. Oxygen in COPD is a drug with a target range, 88 to 92 per cent, not 100. Give controlled oxygen, ideally by venturi mask, to that range, and repeat the blood gas within the hour. If the pH is below 7.35 with a PaCO₂ above 45 mmHg, he needs non-invasive ventilation, and delaying it is the commonest correctable error in the pathway.

Take-home points

• A never-smoking woman who has cooked over a wood fire can have COPD; ask about the kitchen, and do spirometry.
• Stopping smoking does not restore lost lung function, but it is the only thing that slows the decline.
• Do not start LABA + ICS; for a patient already on it, move sideways to LABA + LAMA or up to triple therapy.
• Grade the exacerbation on the patient, and count the respiratory rate yourself for a full minute.
• Oxygen in COPD has a target of 88 to 92 per cent; recheck the gas within the hour.

Read with this: Bronchial Asthma: The Evidence Behind the Pathway, for the disease this one is most often confused with, and Respiratory Auscultation: A Bedside Guide to Breath Sounds.

Declaration: the author built and maintains the tool. It is free to use. The figures in this article are those the tool carried in its Evidence tab on 4 November 2026, each from the source named beside it. The tool is in administrator preview, pending clinical review.

References

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2026 report. GOLD; 2025.
2. Celli BR, Fabbri LM, Aaron SD, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal. Am J Respir Crit Care Med. 2021;204(11):1251-1258.
3. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204.
4. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645-1648.
5. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223-2231.
6. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671-1680.
7. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35-48.
8. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205-214.
9. Sciurba FC, Criner GJ, Christenson SA, et al. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med. 2025;392(17):1710-1720.
10. Gupta D, Agarwal R, Aggarwal AN, et al. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: joint ICS/NCCP (I) recommendations. Lung India. 2013;30(3):228-267.
11. India State-Level Disease Burden Initiative CRD Collaborators. The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018;6(12):e1363-e1374.